"Naltrexone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
| Descriptor ID |
D009271
|
| MeSH Number(s) |
D03.132.577.249.706.550 D03.605.497.750.550 D03.633.400.686.750.550 D04.615.723.795.706.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Naltrexone".
Below are MeSH descriptors whose meaning is more specific than "Naltrexone".
This graph shows the total number of publications written about "Naltrexone" by people in this website by year, and whether "Naltrexone" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 2 | 3 | 5 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 2 | 2 |
| 1999 | 2 | 1 | 3 |
| 2000 | 4 | 5 | 9 |
| 2001 | 3 | 0 | 3 |
| 2002 | 4 | 1 | 5 |
| 2003 | 5 | 4 | 9 |
| 2004 | 1 | 1 | 2 |
| 2005 | 5 | 4 | 9 |
| 2006 | 3 | 3 | 6 |
| 2007 | 4 | 5 | 9 |
| 2008 | 9 | 3 | 12 |
| 2009 | 4 | 7 | 11 |
| 2010 | 9 | 6 | 15 |
| 2011 | 3 | 5 | 8 |
| 2012 | 11 | 5 | 16 |
| 2013 | 10 | 5 | 15 |
| 2014 | 4 | 6 | 10 |
| 2015 | 11 | 6 | 17 |
| 2016 | 11 | 2 | 13 |
| 2017 | 7 | 6 | 13 |
| 2018 | 10 | 4 | 14 |
| 2019 | 8 | 3 | 11 |
| 2020 | 5 | 6 | 11 |
| 2021 | 7 | 11 | 18 |
| 2022 | 4 | 10 | 14 |
| 2023 | 3 | 8 | 11 |
| 2024 | 6 | 1 | 7 |
| 2025 | 1 | 0 | 1 |
Below are the most recent publications written about "Naltrexone" by people in Profiles.
-
Trial protocol of an open-label pilot study of oral naltrexone-bupropion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial). BMJ Open. 2025 Feb 07; 15(2):e092032.
-
Follow-up and reasons for extended-release naltrexone discontinuation for alcohol use disorder after hospital initiation. BMJ Open Qual. 2024 Dec 09; 13(4).
-
Off-label Use of Lamotrigine and Naltrexone in the Treatment of Ketamine Use Disorder: A Case Report. J Addict Med. 2025 Jan-Feb 01; 19(1):112-114.
-
Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder. Pharmaceut Med. 2024 Jul; 38(4):291-302.
-
Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial. Addiction. 2024 Oct; 119(10):1840-1845.
-
Characterizing reward and relief/habit drinking profiles in a study of naltrexone, varenicline, and placebo. Alcohol Alcohol. 2024 May 14; 59(4).
-
Medication-based treatment among rural, primary care patients diagnosed with opioid use disorder and alcohol use disorder. J Subst Use Addict Treat. 2024 Sep; 164:209339.
-
Implementation and analysis of a multifaceted intervention for alcohol use disorder from a single academic urban emergency department. Acad Emerg Med. 2024 05; 31(5):456-462.
-
Nurse Care Management for Opioid Use Disorder Treatment: The PROUD Cluster Randomized Clinical Trial. JAMA Intern Med. 2023 Dec 01; 183(12):1343-1354.
-
A practice quit model to test early efficacy of medications for alcohol use disorder in a randomized clinical trial. Psychopharmacology (Berl). 2024 Mar; 241(3):543-553.